Abstract: Nanotechnology is the study, design, creation, synthesis, manipulation, and application of functional materials, devices, and delivery systems through control of matter at the nanometer scale. These include nanovectors, nanotubes, nanosensors, nanowires and nanocantilever arrays, nanopores and nanoformulations. These advances will lead to significant applications relevant to the diagnosis, management, and in the treatment of many diseases. The application of nanotechnology has attracted much interest as a new approach to deliver poorly soluble drugs in the form of colloidal nano-dispersion "nanosuspension" due to flexibility in processing during manufacturing and benefits like, improvement in oral bioavailability, high drug loading, and targeting capabilities and so on. Nanosuspensions formulation was found to be an efficient delivery system for oral as well as non oral routes like parenteral, ocular, pulmonary and targeted delivery. In this article, we will highlight formulation aspects of nanosuspensions in the light of a brief introduction to the pharmaceutical technology and will summarize the application of nanosuspensions via a variety of administration routes.
INTRODUCTION
The term nanotechnology has been derived from the Greek word 'nano' meaning dwarf, as we currently know it is a burgeoning, multidisciplinary scientific field that applies engineering and manufacturing principles at a molecular level. The development of a wide spectrum of nanoscale technologies is beginning to change the scientific landscape in terms of disease diagnosis, treatment, and prevention.
40% of the active pharmaceutical ingredients (API) obtained by high-throughput screen are poorly soluble molecules [1, 2] . Lower bioavailability results from poor solubility and incomplete dissolution in vivo, often holds back continuous development and coming into the market of some promising new chemical entities (NCEs), or elicits insufficient therapeutic effects of certain drugs. The increasing number of poorly soluble drugs requires innovative formulation approaches to acquire a sufficient bioavailability after oral administration or at least to make available intravenously injectable forms. By adopting appropriate nanoformulation strategies, including lipid-and polymeric based systems (nanoparticles (NPs), nanospheres (NSs), nanocapsules (NCs), nanoemulsions (NEs), self-nanoemulsifying drug delivery systems (SNEDDSs), solid lipid nanoparticles *Address correspondence to this author at the Faculty of Pharmacy; Integral University; Kursi Road; Lucknow-226026 India; Tel: +91-9565402042; E-mail: rahmanpharma@gmail.com (SLNs), nanostructured lipid carriers (NLCs) and so on, these molecules have easily passed through the drug development process pipeline to reach the market.
Nanoformulations are attracting considerable attention due to their capacity to increase the rate of dissolution by increasing the solubility, facilitating gastrointestinal absorption, alleviating positive food effects and reduce inter-and intra subject variability, thus increasing the bioavailability of poorly water soluble drugs [3] . The potential mechanisms responsible for enhanced oral delivery observed with these nanocarriers have been shown in Fig. (1) .
NANOTECHNOLOGY IN THE REALM OF NANO-MEDICINE
Nanotechnology has incorporated advances in a variety of diverse scientific disciplines including molecular biology, chemistry, genomics, physics, material science, and medicine. One area of nanotechnology application that holds the promise of providing great benefits for society in the future is in the realm of medicine. Nanotechnology is already being used as the basis for new, more effective drug delivery systems and is in early stage development as scaffolding in nerve regeneration research. Moreover, the National Cancer Institute (NCI) has created the Alliance for Nanotechnology in Cancer in the hope that investments in this branch of nanomedicine could lead to breakthroughs in terms of detecting, diagnosing, and treating various forms of cancer. Nanotechnology has the opportunity to enhance the detection of pathology by imaging in a specific and sensitive manner, plays an increasingly important role in disease detection and planning of therapy and surgery. Furthermore, clinical trials are depending more on imaging data to provide noninvasive, objective measures of therapy response. In vivo imaging of these nanoscale systems can be carried out by using various types of imaging techniques, including single photon emission computed tomography (SPECT), positron emission tomography (PET), magnetic resonance imaging (MRI), fluorescence microscopy, computed tomography ultrasound and so on.
The explosion in our manipulation of the nanoenvironment and its potential applications has resulted in both the European Union and the United States investing hundreds of millions of dollars into this new discipline. One projection from the US National Science Foundation has estimated that the world market for nanotechnology in 2015 could be as much as $1 trillion [4] . Application of nanotechnology in drug delivery and targeting of therapeutics with nanoformulations and in diagnosis is at the forefront of nanomedicine for several reasons (Tables 1 and 2 ).
NANOFORMULATIONS
In brief, nanoformulations include nanoparticles, are solid, colloidal particles consisting of macromolecular substances that vary in size from 10 nm to 100 nm [12] that can mimic or alter biological processes like infection, tissue engineering, de novo synthesis, etc. Utilizing nanoparticles for disease treatment in a wide range of medical research fields has become a popular strategy in recent years. These particles can serve as carriers for drugs, peptides, vaccines and oligonucleotides and have been successfully delivered to multiple targets including cancerous cells and other diseased tissues. Nanoparticles also have great potential as a strategy for gene therapy and can be used to treat genetic defects in vitro and in vivo.
Nanospheres are matrix systems in which the drug is physically and uniformly dispersed whereas nanocapsules are vesicular systems in which a drug is confined to a cavity surrounded by a polymer membrane. Typically, the drug of interest is dissolved, entrapped, adsorbed, attached and/or encapsulated into or onto a nano-matrix. Depending on the method of preparation nanoparticles, nanospheres, or nano-capsules can be constructed to possess different properties and release characteristics for the best delivery or encapsulation of the therapeutic agent [13, 14] .
Solid lipid nanoparticles (SLNs) are defined as "nanocrystalline suspensions in water prepared from lipids which are solid at room temperature" have advantages such as the use of physiological lipids, avoidance of organic solvents in their preparation, protection of sensitive drugs from the external environment, and controlled release of drugs [15, 16] . SLNs were developed as an alternative carrier system, at the beginning of the 1990s, following the development of emulsions, liposome and polymeric nanoparticles. Compared with traditional carriers, SLN are well tolerated, have high bioavailability, a nice targeting effect and are amenable to large scale production. However, due to the high crystallization of the solid lipids or blends of solid lipids, drugs tend to be released from the nanoparticles, thus leading to drug expulsion and low loading capacity. To overcome the limitations of SLN, a new generation of lipid nanoparticles, nanostructured lipid carriers (NLCs) have been developed in recent years [17] . Nanostructured lipid carriers (NLCs) belonging to the second generation of lipid nanoparticles, can be prepared by blending solid-lipids and liquid-lipids which could result in the less ordered inner structure [17] . The NLC has been considered as an alternative to liposomes and emulsions due to improved properties such as ease of manufacture, high drug loading, and more flexibility in modulating the drug release profile [18, 19] . Furthermore, their aqueous nature, nanostructure and biocompatibility of the excipients would enable Albumin nanoparticles Folate Folate receptor [5] Magnetic nanoparticles Insulin Insulin receptor [6] Lipid nanoparticles Anti-Flk-1 Vascular endothelial growth factor receptor 2 (Flk-1) [7] Polymer nanoparticles RGD peptide Cellular adhesion molecules such as integrins [8] Polymer nanoparticles Luteinizing hormone-releasing hormone Luteinizing hormone-releasing hormone receptor [9] Albumin nanoparticles Gelatinase inhibitory peptide MMP-2 and MMP-9 gelatinase [10] Polymer nanoparticles Aptamers Proteins, peptides, enzymes, antibodies, various cell surface receptors, and small organic molecules [11] intravenous delivery of the drug with passive targeting ability and easy abolishment.
Nanoemulsions (NEs) are isotropic, thermodynamically stable transparent (or translucent) systems of oil, water and surfactant, frequently in combination with a cosurfactant. While self nano-emulsifying drug delivery system (SNEDDS) is an anhydrous system of nanoemulsions. It has also been referred to as nanoemulsion preconcentrate in some literature [3] . It is composed of oil, surfactant and cosurfactant and has the ability to form o/w nanoemulsion when dispersed in aqueous phase under gentle agitation.
NANOSUSPENSION
Nanosuspension is a submicron colloidal dispersion of drug particles in an aqueous vehicle which are stabilized by surfactants with particle size distribution of usually less than one micron with an average particle size ranging between 200 and 600 nm [20, 21] . As mentioned above, most of the new chemical entities being generated through drug discovery programmes are poorly water-soluble. The problem is even more intense for drugs that are poorly soluble in both aqueous and organic media, and for drugs having a log P value of 2. Such drugs often have an erratic absorption profile and highly variable bioavailability because their performance is dissolution-rate limited and is affected by the fed/fasted state of the patient.
Traditional strategies, such as micronization, solubilization using co-solvents, the use of permeation enhancers, oily solutions and surfactant dispersions, which evolved earlier to tackle the formulation challenges, have limited use. Although reasonable success has been achieved in formulating water-insoluble drugs using liposomes, emulsions, microemulsions, solid dispersion technology and inclusion complexes employing cyclodextrins, there is no universal approach applicable to all drugs. Hence, there is a growing need for a unique strategy that can tackle the formulationrelated problems associated with the delivery of hydrophobic drugs in order to improve their clinical efficacy and optimize their therapy with respect to pharmacoeconomics. Nanosuspensions have revealed their potential to tackle the problems associated with the delivery of poorly water-soluble and poorly water-and lipid-soluble drugs, and are unique because of their simplicity and the advantages they confer over other strategies. This review focuses on the various aspects of nanosuspensions and their potential as a promising strategy in drug delivery. In nanosuspension formulation, the drug is required to maintain in crystalline state with reduced particle size, leading to an increased dissolution rate and thus improved bioavailability. Increase in the dissolution rate of submicronized particles is due to increase in the surface area and consequently the dissolution rate.
Because of the vapor pressure effect these nanosized particles can also increase solution velocity and saturation solubility [20] . In addition to that, the diffusional distance on the surface of drug nanoparticles is decreased, leading to increase in concentration gradient. Both, increases in surface area and concentration gradient lead to a much more pronounced enhancement of dissolution velocity and saturation solubility as compared to micronized product. Another possible explanation for increased saturation solubility is the creation of high energy surfaces when disrupting more or less ideal drug microcrystals to nanoparticles. When formulating nanosuspension, dissolution experiments can be performed to quantify the increase in the saturation solubility of the drug [22] .
Crystal growth and formation of microparticles in nanosuspension caused by difference in dissolution pressure and saturation solubility created by wide range distribution in particles called "Ostwald ripening". Molecules from higher concentration area around small particles diffuse to an area around larger particles possessing a lower drug concentration. This leads to the formation of a supersaturated solution around the large particles lead to crystallization and formation of microparticles. Stability of nanosuspension formulation is due to uniformity in particle size distribution which prevents the existence of different saturation solubility and concentration gradient, consequently preventing the Oswald ripening effect [23] . Nanosuspensions are considered as a potential formulation to sort out the problems associated with the delivery of both poorly water soluble and poorly water and lipid soluble drugs.
MANUFACTURING PROCESSES
In brief; for the nanosuspensions manufacture, there are two converse methods 'bottom-up' and the 'top-down' technologies. The bottom-up technology is an assembling method from molecules to nano-sized particles, including microprecipitation, microemulsion, melt emulsification method and so on. The top-down technology is a disintegration approach from large particles, microparticles to nanoparticles, such as high-pressure homogenization and media milling method. The process and principles of the methods has already been discussed in various literatures [23, 24] . The Advantages and disadvantages of all the manufacturing process has been discussed in Table 3 .
EXCIPIENTS SELECTION: RATIONALE APPROACH Stabilizers
During the formulation of nanosuspension suitable stabilizers are needed to stabilize the nanoparticles against interparticle forces and to prevent them from aggregation. In the absence of suitable stabilizer, agglomeration or aggregation of the drug crystals can be induced due to high surface energy of nano-sized particles. Due to dispersion or van der Waals forces, attractive forces exist between particles at the nanometer domain [23, 25] which increases dramatically resulting in an irreversible aggregation. To overcome the attractive forces, repulsive forces are required. "Steric stabilization and electrostatic stabilization" are two different modes of imparting repulsive forces. Adsorption of polymers onto the particle surface results in steric stabilization. When the particles approach each other, the osmotic stress created by the encroaching steric layers keeps the particles separate. However, adsorption of charged molecules (ionic surfactants /charged polymers) onto the particle surface results in electrostatic stabilization. Repulsion among charged molecule provides an electrostatic potential barrier to particle aggregation. Typically, the use of steric stabilization alone is sufficient to stabilize the nanoparticles and to prevent irreversible aggregation. However, enough attractive force between par-ticles may still remain to cause a loose and reversible flocculation. To circumvent flocculation, steric stabilization is often combined with electrostatic stabilization for additional repulsive contribution. Physical stability and in-vivo performance of nanosuspensions largely depend on the type and amount of stabilizers used in the formulation during manufacturing In most of the cases, stable formulations are obtained at weight ratios of drug to stabilizer of 20:1-2:1.
Cellulosics polymers, such as methylcellulose (MC), hydroxypropylcellulose (HPC) and hydroxypropylmethylcellulose (HPMC), povidone (PVP K30), pluronics (F68 and F127) and lecithins are commonly used stabilizers [26] [27] [28] . Non-ionic surfactants, such as polysorbate (Tween 80), or anionic, such as sodium laurylsulfate (SLS) and docusate sodium (DOSS) are sometimes used as surfactant stabilizers. Due to their antiseptic properties, cationic surfactants are typically not used as stabilizers for oral formulation. Incorporation of lecithin to parenteral formulations lead to an acceptable and autoclavable nanosuspension.
Redispersants
Nanoparticles are usually produced in the liquid media, that is, nanosuspensions. The nanosuspensions usually have the stability issues involved in the physical (e.g. Ostwald ripening and agglomeration) and chemical (e.g. hydrolysis) processes. In this case, solid dosage forms are considered more attractive, due to their patient convenience (marketing aspects) and good stability. Therefore, transformation of nanosuspensions into the solid dosage form is desirable. Redispersants need to be added to the nanosuspension to ensure complete redispersion of nanoparticles prior to drying steps. For oral formulation, sugars such as sucrose, lactose, and mannitol are used as redispersants [29, 30] .
Organic Solvents
"Emulsion or microemulsion" as templates are used in some cases to formulate nanosuspension. In such condition, organic solvents may be required. Organic solvents used should be pharmaceutically acceptable and less hazardous such as ethanol and isopropanol, and partially water-miscible solvents, such as ethyl acetate, ethyl formate, butyl lactate, triacetin, propylene carbonate and benzyl alcohol, are preferred in the formulation [23] .
Co-surfactant
When using microemulsions to formulate nanosuspensions, choice of co-surfactant is critical. Use of bile salts and dipotassium glycerrhizinate has been in described as potential co-surfactants in the literature. Transcutol, glycofurol, ethanol and isopropanol, can also be safely used as cosurfactants in the formulation of microemulsions. Nanosuspension formulation may contain other additives such as chelating agents for cavenging of metal ions, preservatives for multidose products, buffer for pH adjustment, additional polymers as bioadhesives and matrices for sustained release, osmogent and cryoprotectant for tonicity adjustment and other additional functions, depending on route of administration or properties of active moiety [23] .
FORMULATION: TECHNOLOGICAL CONSIDERA-TION
While formulating nanosuspension, it is ensured that not only the drug particles be rendered into nanosized domains, but they must also be stabilized and formulated rigorously to retain the nature and properties of the nanoparticles. 'Top down' and 'bottom up' technologies are two main approaches for manufacturing nanoparticles for nanosuspension [31, 32] .
'Top down' approaches are typically based on the principle of mechanical attrition to render large crystalline particles into nanoparticles. While 'bottom-up' technology involves dissolving the drug in a solvent and precipitating it in a controlled manner to nanoparticles through addition of an anti-solvent in the presence of surfactant. Examples of the The manufacturing process is complicated.
Melt emulsification Avoidance of organic solvents compared to the solvent diffusion Few compliant objects, larger particles from it than solvent diffusion 'top down' approach include NanoCrystal ® wet-milling technology (trademark of NanoSystems, a business unit of the Elan Corporation) [29] and Dissocubes ® high-pressure homogenization technology (registered trademark of DDSDrug Delivery Services GmbH/Krohnshagen, Germany) [31, 33] . The 'bottom-up' technology is available from DowPharma (Midland, MI, USA) and BASF Pharma Solutions (Florham Park, NJ, USA). Muller and coworkers have produced drug nanoparticles (Dissocubes) by piston-gap homogenization [34] . In some cases, micronization of the raw material was required before homogenization in order to obtain the desired final particle size. Muller and coauthors have suggested jet milling or ball milling as a size reduction step prior to piston-gap homogenization [35] .
Baxter's NANOEDGE ® technology (registered trademark of Baxter International Inc.) used a hybrid technology by employing both 'bottom up' and 'top down' approaches through microprecipitation and homogenization [31] . NANOEDGE process relies on the precipitation of friable materials for subsequent fragmentation under conditions of high shear and/or thermal energy [36, 37] . This is accomplished by a combination of rapid precipitation and highpressure homogenization. Rapid addition of a drug solution to an anti-solvent leads to sudden supersaturation of the mixed solution, and generation of fine crystalline or amorphous solids. Precipitation of amorphous material may be favored at high supersaturation when the solubility of the amorphous state is exceeded. Furthermore, high supersaturation often favors formation of slender, needle-like crystals. This is in accord with the general Ostwald-Mier theory wherein supersaturation favors nucleation rather than crystal growth [38] . From Eq. (below), if the density of the particle ( ) and the solid-liquid interfacial tension ( ) are constant, a high supersaturation (left-hand side of Equation) may be compensated by a lower critical nucleation radius, r.
In S/S0 = 2 /rRT = 2M / rRT
Thus homogeneous nucleation in the highly supersaturated environment produced from rapid mixing will favor the generation of many small nuclei that quickly grow and deplete the drug in the supernatant phase. This should result in formation of many small crystals [39] . The precipitated nanosuspension is stabilized during processing by surfactants that are added to the drug solution, anti-solvent, or both. These additives may also inhibit crystal growth. It is also known in crystallization studies that as supersaturation is progressively increased, the interface morphology eventually leads to needle like, or dendritic growth [40] . Because of their small size and shape, particles produced by rapid precipitation are often more friable than the starting material and hence more susceptible to fragmentation [36] . Modeled on a cantilever analogy [41] , the yield force required to break individual crystals must vary inversely with the second to third power of the crystal thickness. If lattice defects, inclusions, or amorphous domains are also introduced, then the yield force should further decrease.
POST-PRODUCTION DRYING
Conventional dryer such as fluid-bed dryer and spray dryer can be used to dry nanoparticles as they are usually produced in the liquid media. Drying of nanoparticles can create stress on the particles that can cause aggregation. Due to the above considerations, adding matrix-formers to the suspension prior to solidification is necessary. At present, except for traditional lyoprotectants (such as glucose, sucrose, trehalose, lactose, mannitol, sorbitol, maltose and dextran) [42] [43] [44] , some new matrix-formers have received significant interest.
Van Eerdenbrugh et al. had successfully used microcrystalline cellulose to displace sucrose as a matrix former during freeze-drying of itraconazole nanosuspensions [45] , and had again evaluated four alternative matrix formers [Avicel ® PH101, Fujicalin ® (CaHPO4), Aerosil ® 200 (SiO2) and Inutec ® SP1] for their capability in preserving rapid dissolution after spray-drying of nanosuspensions [46] . In addition, the effect of surface hydrophobicity on drug dissolution behavior upon redispersion had been investigated, indicating the more intense hydrophobicity, the more aggregation of the nanoparticles and the slower the drug's dissolution after solidification [47] . Post drying steps include roller compaction/encapsulation/ tableting/pelletization (either by extrusion spheronization or freeze pelletization technique) of the dried materials [48] .
Identification of redispersible solid nanoformulation and suitability of drying process are considered to be main goal during early-phase development. Screening of redispersants and stabilizers for suitability as well as desirable performance of the product can be performed in a small-scale dryer, such as the Mini-Glatt [Glatt Air Techniques, Inc., Ramsey, NJ], or in a lab-scale spray dryer, such as the Buchi [Buchi Corp., Newcastle, DE] and the Niro [Niro, Inc., Columbia, MD] [49] . 'Spray-drying' in spite of robustness and meeting all the processing needs of an early-phase development not preferred for scale-up. While, fluid-bed drying in the form of either fluid-bed coating or granulation would be more scalable, but its process is more difficult to optimize with small quantity of active ingredients. Emphasis is shifted to process optimization and scale-up at late-phase development of solid nanoformulation.
CHARACTERIZATION
Safety, efficacy and stability of nanoformulation are affected by the particle size, particle size distribution and zeta potential; solid state of nanoparticles influences the dissolution performance by impact forces that shatter the lattice along dislocation boundaries. So the nanoparticles characterization is of a great importance to predict in vitro and in vivo performance.
There are mainly two appropriate and suitable techniques in use for characterization of nanoparticles in nanosuspension. The first technique deals with attributes and properties of single nanoparticles, such as their particle size and surface charge (zeta potential). Particle crystallinity, dissolution, and surface coverage also covered under this technique. The second technique measures bulk properties, such as the viscosity. Redispersibility testing is additionally used to evaluate the redispersion of solid nanoformulations in relevant media, such as water and gastric fluid. Nanoparticle size has an impotant influence on satuaration solubility and dissolution rate of nanoformulation. Noyes-Whitney equation [50, 51] , Ostwald-Freundlich equation [52, 53] , Kelvin equation [54] [55] [56] and the Prandtl equation [57] could be used to explain the relationships among particle size, saturation solubility and dissolution rate of nanoformulations.
'Laser light scattering (LLS)' is a popular technique to measure size of nanoparticles, which quickly determine the particle size and distribution. One model that has been frequently used is the Horiba LA-910, measures size range from 50 nm to 1000 Im. The advantageous feature of this technique is that they employed only a few drops of nanosuspensions after dilution into aqueous media.
Particle size could be measured by several other techniques such as laser diffractometry (LD), can detect and quantify the drug microparticles during the manufacturing process, yields a volume size distribution and can be used to measure particles ranging from 0.05 m up to 2000 m, photon correlation spectroscopy (PCS), measuring range is from 3 nm to 3 m [58] , and coulter-counter which gives the absolute number of particles per volume unit for the different size classes. In an experiment, Gao et al had studied the effect of particle size on in-vivo pharmacokinetic behavior of oridonin (ORI) nanosuspensions following intravenous administration in rats. ORI nanosuspensions with a mean particle size 103.3±15 nm were quickly removed from the circulating system. On the contrary, ORI nanosuspension with a mean particle size 897.2±14.2 nm exhibited a markedly delayed blood clearance and a high uptake in reticuloendothelial system (RES) organs [59] .
'Surface charge' is another fundamental property of nanoparticles is estimated through measurements of the zeta potential. Zeta potential is the potential at the hydrodynamic shear plane and can be determined from the particle mobility under an applied electric field [25] During nanosizing, drug might undergo polymorphic or morphological changes. These changes can be understandable with the help of crystallinity and surface morphology. Additionally, during nanosuspensions formulation, crystalline state of the drug is likely to be partially converted to an amorphous state. Hence, it is essential to measure the extent of amorphous drug formation during the nanosuspensions formulation. By X-ray diffraction analysis changes in the solid state of the drug particles as well as the extent of the amorphous fraction can be determined [60, 61] and supple- mented by differential scanning calorimetry [62, 63] . In order to know about actual understanding of particle morphology, the techniques such as scanning electron microscopy (SEM) [64, 65] , atomic force microscope [65, 66] or transmission electron microscopy (TEM) [66, 67] are preferred.
PHARMACOKINETIC PERFORMANCE
For successful preparation of nanoformulation, monitoring of its biological performance is essential which can be done by establishments of in-vitro/in-vivo correlation. In case of orally administered nanosuspensions, the drug dissolution rate can influence in-vivo biological performance of formulations to a larger extent. For instance, albendazole nanosuspensions was shown to enhanced the C max to 1.5-2 times than that of microsuspension, and increased the AUC 0-and the relative bioavailability (Fr) by 1-2 times than those of microsuspension [68] (Fig. (2) . Hydrophobic interaction chromatography techniques can be used to determine surface hydrophobicity [69, 70] , whereas techniques such as 2-D PAGE [71] can be used for the quantitative and qualitative measurement of protein adsorption after intravenous injection of drug nanosuspensions in animals.
DRUG DELIVERY APPLICATION
Nanosuspensions have been used to prepare diverse dosage forms by post-production processing. At present, there are many drugs in the form of nanosuspensions to be reported and marketed ( Table 4 and 5) via the various administration routes, including oral, parenteral, ophthalmic and pulmonary routes. 
ORAL DELIVERY
In general, oral administration is first choice for various drugs due to well known advantages such as, good patient compliance, simple manufacture process and readily transportation. When a formulation is intended for oral administration, in vivo performance of that formulation depends on the solubility and absorption of drug through the gastrointestinal tract. For those drug candidates exhibiting poor aqueous solubility, release of drug from dosage form are considered to be dissolution rate limited, leading to poor oral bioavailability, high intra-and inter-subject variability and lack of dose proportionality. In such a condition, drugs are administered in large excess to achieve and maintain therapeutic concentration, making high cost of the product leads to costly therapy.
Significant increase in surface area after nanosizing of low/highly variable bioavailable drug increases its saturation solubility and thus increased concentration gradient between the gastrointestinal tract lumen and blood, leads to dramatic improvement in oral absorption as well as subsequent bioavailability. This improvement in bioavailability will lead to a subsequent reduction in dose of the drug, making the therapy cost-effective and prevent drug dumping in the body. Nowadays, one of the nanoformulations like oral nanosuspension has been used to increase the rate of absorption and thus its bioavailability. In one of the study, nanosuspension of azithromycin was formulated in order to improve its dissolution and bioavailability and compared it with micronized drugs of same drug. It was found that the dissolution rate was significantly increased (>65% in 5 h) as compared to micronized drugs which was only 20% [82] .
Atovaquone is an important antibiotic used in the treatment of infectious diseases like Pneumocystis carinii infections in HIV patients, leishmanial infection and in the treatment of non-complicated P. falciparum malaria. Due to poor aqueous solubility, it shows dissolution-rate limited absorption and hence poor oral bioavailability (10-15%). For effective treatment it needs to be administered in high doses (750 mg twice daily). Formulation of Atovaquone as a nanosuspension and its administration resulted in a 2.5-fold increase in oral bioavailability as compared to the commercially marketed product Wellvone containing the active constituent in micronized state [23, 90] . This drastic improvement in bioavailability is considered to be because of the high adhesiveness of the drug particles sticking on biological surfaces of the epithelial gut wall.
Improved oral bioavailability was also found in case of Danazol nanosuspension as compared to commercial danazol macrosuspension. Danazol is a gonadotropin inhibitor, poorly water soluble shows low bioavailability with intersubject variability in fed and fasted state. When administered in the form of nanosuspension, it showed a drastic improvement in absolute bioavailability (82.3%), resulted in a reduction in the inter-subject variability, as compared to the commercially available marketed product danazol macrosuspension Danocrine (5.2%) [91] (Fig. 3). Amphotericin B is an effective antimicrobials frequently prescribed by physicians for treatment of systemic mycoses and leishmaniasis. It shows poor aqueous solubility and oral bioavailability. Oral administration of amphotericin B as a nanosuspension formulation produced a substantial improvement in oral absorption as compared to conventional commercial formulations such as Fungizone, AmBisome and micronized amphotericin B [28] . It was observed that high uptake of drug from nanoparticulate system was brought about through the gastrointestinal tract and it was found that a considerable reduction in the number of L. donovani parasites in the liver of infected female Balb/c mice seen as compared to other commercial formulations [28] (Fig. 4) .
Bupravaquone nanosuspensions have been used for the
Cryptosporidium parvum infection, the main pathogen causing severe diarrhea in immunosuppressant HIV patients. In comparison to the micronized drug powder, the infectivity score was reduced from 2.0 to 1.47 for micronized bupravaquone and even to 1.02 for equivalent nanosuspensions [33] .
The problems associated with many drugs are; they are completely absorbed but shows slower onset of action i.e., it takes longer time to achieve therapeutic plasma concentration (high t max value). Nanosuspension formulations are proved to be advantageous and efficient for quick onset of action. A model drug "naproxen" was selected and formulated in various formulations, nanosuspension, suspension (Naprosyn) and tablet (Anaprox), and compared its pharmacokinetic profile. It was observed that t max reduced by approximately 50% and AUCs increased 2.5-4.5 folds during the first hour of the study for the nanosuspension compared to the suspension and tablet [23, 29] .
PARENTERAL DELIVERY
When the drug is not absorbed through the gastrointestinal tract or undergoes extensive first-pass metabolism, parenteral route is often employed as an alternative route for such drugs. The formulation strategies for parenteral delivery include salt formation, solubilization using co-solvents, micellar solutions [92] , and complexation with cyclodextrins [93] . However, there are several drawbacks using these approaches because of limitations on their solubilization capacity and parenteral acceptability. Liposomes are much more tolerable and versatile in this regard for parenteral delivery irrespective of problems such as instability, high manufacturing cost and difficulties in scale-up.
Paclitaxel is one of the most potent chemotherapeutic agents currently employed for the treatment of solid tumors. However, it is a very lyophobic compound; insoluble in most pharmaceutically acceptable solvents. Therefore, it is formulated in a 1:1 combination of polyoxyethylated castor oil (Cremophor ® EL) and dehydrated ethanol for i.v. use and is currently marketed as Taxol ® . In order to evaluate the tolerance level and death rate of the nanosuspension formulation, a study was conducted in MV-522 human lung xenograft murine tumor model, and compared with the available marketed product Taxol ® . The tolerance level was three times higher than the marketed product Taxol ® . No cases of death rate were found associated with paclitaxel nanosuspensions at doses of 90 and 100 mg kg -1 , whereas Taxol ® showed a death rate of 22% at a concentration of 30mg kg -1 [23, 29, 94] . Study on certain other anti-cancer agents (etoposide and camptothecin) in nanosuspension formulation revealed an improvement in the tolerance level as compared to the marketed formulations. In addition, nanosuspensions have been found to increase the efficacy of the parenterally administered drug [66] .
In a study, the efficacy of an intravenous liposomal preparation against Mycobacterium avium was compared to that of a clofazimine nanosuspension that was prepared by high-pressure, piston-gap homogenization. The drug was insoluble in aqueous formulations and was found to be toxic at therapeutically significant doses. The liposomal formulation had been found to be highly effective in artificially induced M. avium infections. However, the degree of drug loading per volume was appreciably lower in the liposomal preparation than in the nanosuspension. The clofazimine nanosuspension (20 mg/kg), delivered intravenously to mice, was as effective as the liposomal formulation in targeting the RES, and concentrations of clofazimine in the lung, liver and spleen were comparable. Moreover, these concentrations far exceeded the MIC for most strains of M. avium [84] .
OCULAR DELIVERY
For effective treatment of most of the ocular diseases and for avoidance of tonicity created by water soluble drugs, it is desirable that the formulation should have prolonged residence time in a cul-de-sac. These benefits are offered by suspension. The nanometer size represents a state of matter characterized by higher solubility, higher surface area available for high dissolution, better bioadhesion and corneal penetration, and less frequent instillation.
In one of the study, polymeric nanosuspension of ibuprofen was prepared for ophathamic controlled delivery using Eudragit RS100 as polymer by quasi-emulsion and solvent diffusion method and in-vivo performance was estimated and compared it with existing marketed formulations [23, 95] . The successfully developed polymeric nanosuspensions was characterized for drug loading capacity, particle size measurement, zeta potential, in-vitro drug release behavior, ocular tolerability and in-vivo biological performance. The developed nanosuspension formulation offered superior in-vivo performance over the existing marketed formulations and could sustain drug release for 24 h. Nanosuspensions of glucocorticoid drugs; hydrocortisone, prednisolone and dexamethasone enhance rate, drug absorption and increase the duration of drug action [23, 89] .
Besides the natural bioadhesion of the nanoparticulate, surface charge and modified surface by suitable gel matrix and bioadhesive matrix allow prolonged residence time and sustained release of the drug in the cul-de-sac. If nanoparticles have a positive charge, significant improvement in drug performance can be achieved. The positive charge present in these nanoparticles could account for a strong interaction with the negatively charged mucosa of the conjunctiva, thus allowing for a sufficient residence time to permit an efficient drug release [95, 96] . Wrapping nanosuspensions in appropriate gel matrix or bioadhesive matrix is another technique to prolong retention time. After surface modification by biodegradable hydrophilic polymer, flurbiprofen nanosuspensions demonstrated good effect of sustained-release following ocular administration [96] .
PULMONARY DELIVERY
Over years, solution, microsuspension, and dry powder as conventional formulations were used in the preclinical studies. The utility of these formulations, however, has some limitations in the preparation and delivery. For example, vehicle tolerability of solution formulations [97] , limited diffusion and dissolution of the drug, rapid clearance of the drug from the lungs [98] , less residence time, highly variable lung deposition and exposure of microsuspensions [99] [100] [101] are formidable problems associated with pulmonary drug delivery.
Nanosuspensions can solve the problems associated with conventional systems because of their versatile nature. Nanosuspensions employed for pulmonary delivery can be nebulized using mechanical or ultrasonic nebulizers. Nanosuspensions are available and can be used in all types of nebulizer. But, it should be ascertained about the extent of influence exerted by the nebulizer type as well as the nebulization process on the particle size of nanosuspensions.
Additionally, for successful development and effective therapy, it is required that there should be uniform distribution of nanoparticles in the formulation and at least one nanoparticle should be contained in each aerosol droplet for even distribution of drug in the lungs. It has been observed in conventional suspension aerosols, many droplets are drug free and others are highly loaded with the drug, leading to uneven delivery and distribution of the drug in the lungs.
Pulmonary delivery of budesonide in form of a nanocrystal suspension has been suggested for the treatment of steroid-responsive pulmonary diseases such as asthma [23, 87] . Budesonide is a poorly water-soluble compound that is available as a suspension for inhalation (Pulmicort Respules) with a nebulizer. The particle size of suspended particles is approximately 4.4 Am. The nanosuspension of budesonide that was suggested as an alternative was prepared employing the Nanocrystal ® technology with particles in the range of 75-300 nm. The safety, delivery, and pharmacokinetics of nebulized nanobudesonide and Pulmicort Respules was evaluated in a randomized, double-blind, single-dose crossover study involving 16 healthy volunteers. Overall, both nebulized formulations were well tolerated. Nanobudesonide and Pulmicort Respules resulted in similar AUCs, suggesting a similar extent of pulmonary absorption. However, a higher C max was seen with nanobudesonide and in addition the t max was significantly smaller. Finally, nebulization of nanobudesonide resulted in significantly shorter nebulization times compared with Pulmicort Respules, which is advantageous with respect to patient compliance.
TARGETED DELIVERY
For a drug to exert its desired effect it needs to be in physical contact with its physiological target, such as a receptor. Site-selective drug delivery ensures that such interactions take place only in the desired anatomical location of the body. Although, in principle, every drug might benefit from site-selective delivery not every drug is equally suitable for the process. Drugs that are not retained at the site of action for a long enough period of time will not benefit from sitespecific release. Also, drugs that have the same site for efficacy and toxicity will not improve through site-selective delivery and their effect: side-effect ratio could even get worse. Evidently, drugs that already have an inherently high specificity for reaching and interacting with their targets, for example therapeutic antibodies, do not need to be considered for targeting [23] .
Targeting drug to specific sites is considered to be beneficial both therapeutically and economically. Due to these reasons use of drug targeting in therapy are increasing day by day. Various formulation approaches including potential nanosuspension can be used to target the drug to specific sites as their surface properties and in vivo behavior can easily be altered by changing either the stabilizer or the milieu. Also, scale up technique is easy for nanosuspension formulation. The engineering of stealth nanosuspensions by using various surface coatings for active or passive targeting of the desired site is the future of targeted drug delivery systems. Cryptosporidium parvum is an organism responsible for cryptosporidiosis. For the treatment of cryptosporidiosis, formulation strategy was planned by targeting; and was achieved by using surface modified mucoadhesive nanosuspensions of bupravaquone [102] . Similarly, targeting of pulmonary aspergillosis can be easily achieved by using pulmonary nanosuspensions incorporated with suitable drug candidates, such as amphotericin B [23, 103] .
A tremendous potential by nanoparticulate system has been shown in targeted drug delivery, especially to the brain [104] . Site-specific delivery of peptide dalargin to the brain by employing surface modified polyisobutyl cyanoacrylate nanoparticles has been a major scientific achievement in targeted delivery [105] . Polymeric nanosuspensions loaded with drug, it should be possible to target sites, such as the colon, or bacteria, such as H. pylori, by suitable modifications in the formulation strategy. Overall, nanosuspensions have indicated a good potential in targeted drug delivery but this has yet to be fulfilled.
CONCLUSION
The field of nanomedicine has a bright future with the emergence of several promising approaches for delivery of therapeutic agents and imaging using the advantages of the nanoscale carriers. Various initiatives from both the federal agencies as well as industry support the continual research into the application of nanotechnology to improve drug delivery and molecular imaging. Over the last 20 years, many of the major breakthroughs in medicine have come not from treatment but from imaging, identification and characterization of disease processes.
One of the nanoformulation approaches in the form of nanosuspension is considered as the most promising delivery system for poorly soluble drugs, due to high bioavailability and less inter-and intra-subjects variances. It is proved suitable to formulate various poorly soluble drugs, in particular for the brick-dust molecules poorly soluble in both water and lipids, and can reduce the social investment and enhance the success rate in insoluble drug development.
Altered pharmacokinetic profiles of drugs caused by nanosuspensions have become appreciable insofar as they improve safety and efficacy. So the study on in vivo biological performance is extremely important, and the establishment of an in vitro/in vivo relationship will become a hot research field in the further study of nanosuspensions.
Additionally, their applications in buccal, nasal and topical delivery will represent a more beautiful prospective. Surface modification of the drug nanosuspensions can further increase the benefits, e.g. stabilizing blood level of drugs by controlling drug release and targeting specific organ by using special surface ligands. Controlled drug release and functionalized surface coatings capable of eliciting passive or active targeting, will be regarded as the future promising step in the nanosuspensions research.
